Turmeric trial for cervical precancer pulled before it began
NCT ID NCT02554344
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial aimed to test whether curcumin (the active compound in turmeric) could safely help treat cervical precancer (CIN3). It planned to give 500 mg of curcumin twice daily for 12 weeks to women with CIN3. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
curcumin (turmeric extract)
What this could lead to
If it had worked, this could have pointed toward a simple, low-cost supplement to help treat cervical precancer.
What could go wrong
The trial was withdrawn before any participants enrolled, so we have no data on safety or effectiveness. Curcumin is poorly absorbed, and early-phase studies often fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States